Pfizer Inc. $PFE Shares Acquired by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners boosted its Pfizer stake by 17.5% in the first quarter, buying 425,669 additional shares and ending with 2.85 million shares worth about $80.2 million.
• Pfizer reported better-than-expected quarterly results, posting $0.75 EPS on $14.45 billion in revenue, while also maintaining full-year 2026 EPS guidance of $2.80 to $3.00.
• The company continues to offer a high dividend yield of about 7.0%, but analysts remain cautious overall, with a consensus rating of Hold and a target price around $28.50.

Epoch Investment Partners Inc. increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,854,601 shares of the biopharmaceutical company's stock after buying an additional 425,669 shares during the period. Epoch Investment Partners Inc. owned about 0.05% of Pfizer worth $80,157,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. TCM Advisors LLC lifted its position in shares of Pfizer by 4.3% during the first quarter. TCM Advisors LLC now owns 35,240 shares of the biopharmaceutical company's stock worth $990,000 after purchasing an additional 1,450 shares during the last quarter. St. Louis Trust Co increased its holdings in Pfizer by 0.8% in the first quarter. St. Louis Trust Co now owns 53,894 shares of the biopharmaceutical company's stock valued at $1,513,000 after buying an additional 423 shares during the last quarter. Bridgewater Advisors Inc. raised its stake in Pfizer by 3.8% during the first quarter. Bridgewater Advisors Inc. now owns 67,640 shares of the biopharmaceutical company's stock valued at $1,756,000 after buying an additional 2,450 shares in the last quarter. Dai ichi Life Insurance Company Ltd lifted its holdings in Pfizer by 8.9% during the 1st quarter. Dai ichi Life Insurance Company Ltd now owns 242,836 shares of the biopharmaceutical company's stock worth $6,819,000 after buying an additional 19,771 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its holdings in Pfizer by 1.6% during the 1st quarter. Gamco Investors INC. ET AL now owns 589,634 shares of the biopharmaceutical company's stock worth $16,557,000 after buying an additional 9,303 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.9%

Shares of NYSE PFE opened at $24.52 on Friday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a market cap of $139.78 billion, a price-to-earnings ratio of 18.72 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock's 50 day simple moving average is $25.11 and its 200 day simple moving average is $26.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm's revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is 131.30%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. UBS Group reissued a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Cantor Fitzgerald restated a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Finally, Guggenheim decreased their price target on shares of Pfizer from $36.00 to $35.00 and set a "buy" rating for the company in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.